NASDAQ:IMVT

Immunovant Competitors

Top-Rated Stocks

$15.42

-0.46 (-2.90 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$15.25

Now: $15.42▼

$15.93

50-Day Range

$13.08

MA: $15.87▼

$17.17

52-Week Range

$11.80

Now: $15.42▼

$53.75

Volume559,497 shs

Average Volume1.47 million shs

Market Capitalization$1.51 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Immunovant (NASDAQ:IMVT) Vs. KOD, ADPT, VIR, CBPO, ALLO, and BEAM

Should you be buying IMVT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Immunovant, including Kodiak Sciences (KOD), Adaptive Biotechnologies (ADPT), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), and Beam Therapeutics (BEAM).

Immunovant vs. Kodiak Sciences Stock

Kodiak Sciences (NASDAQ:KOD) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Kodiak Sciences and Immunovant's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-32.32%	-23.86%
Immunovant	N/A	-34.80%	-32.38%

Analyst Ratings

This is a summary of recent ratings for Kodiak Sciences and Immunovant, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1	7	4	0	2.25
Immunovant	0	1	14	0	2.93

Kodiak Sciences presently has a consensus price target of $129.9091, indicating a potential upside of 14.39%. Immunovant has a consensus price target of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Kodiak Sciences.

Earnings & Valuation

This table compares Kodiak Sciences and Immunovant's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	$-47,370,000.00	($1.25)	-91.91
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01

Kodiak Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 40.2% of Immunovant shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 0.2% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kodiak Sciences beats Immunovant on 6 of the 10 factors compared between the two stocks.

Immunovant vs. Adaptive Biotechnologies Stock

Immunovant (NASDAQ:IMVT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider & Institutional Ownership

40.2% of Immunovant shares are owned by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are owned by institutional investors. 0.2% of Immunovant shares are owned by insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Immunovant and Adaptive Biotechnologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-34.80%	-32.38%
Adaptive Biotechnologies	-132.32%	-20.15%	-13.09%

Valuation and Earnings

This table compares Immunovant and Adaptive Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01
Adaptive Biotechnologies	$85.07 million	68.78	$-68,610,000.00	($1.01)	-41.61

Immunovant has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Immunovant and Adaptive Biotechnologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	1	14	0	2.93
Adaptive Biotechnologies	0	2	4	0	2.67

Immunovant currently has a consensus price target of $45.60, indicating a potential upside of 192.68%. Adaptive Biotechnologies has a consensus price target of $61.40, indicating a potential upside of 46.71%. Given Immunovant's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunovant is more favorable than Adaptive Biotechnologies.

Immunovant vs. Vir Biotechnology Stock

Vir Biotechnology (NASDAQ:VIR) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

54.5% of Vir Biotechnology shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 37.2% of Vir Biotechnology shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and Immunovant's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-339.61%	-47.11%	-39.44%
Immunovant	N/A	-34.80%	-32.38%

Valuation & Earnings

This table compares Vir Biotechnology and Immunovant's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$8.09 million	726.46	$-174,680,000.00	($5.76)	-7.97
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01

Immunovant has lower revenue, but higher earnings than Vir Biotechnology. Immunovant is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vir Biotechnology and Immunovant, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2	0	5	0	2.43
Immunovant	0	1	14	0	2.93

Vir Biotechnology currently has a consensus target price of $66.00, indicating a potential upside of 43.73%. Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Vir Biotechnology.

Summary

Immunovant beats Vir Biotechnology on 9 of the 12 factors compared between the two stocks.

Immunovant vs. China Biologic Products Stock

China Biologic Products (NASDAQ:CBPO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

34.8% of China Biologic Products shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 2.7% of China Biologic Products shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares China Biologic Products and Immunovant's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Biologic Products	27.43%	8.32%	7.64%
Immunovant	N/A	-34.80%	-32.38%

Valuation & Earnings

This table compares China Biologic Products and Immunovant's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Biologic Products	$503.70 million	9.24	$138.81 million	$4.28	27.63
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01

China Biologic Products has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for China Biologic Products and Immunovant, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Biologic Products	0	0	0	0	N/A
Immunovant	0	1	14	0	2.93

Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than China Biologic Products.

Summary

China Biologic Products beats Immunovant on 8 of the 11 factors compared between the two stocks.

Immunovant vs. Allogene Therapeutics Stock

Allogene Therapeutics (NASDAQ:ALLO) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Allogene Therapeutics and Immunovant's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-27.59%	-24.97%
Immunovant	N/A	-34.80%	-32.38%

Valuation & Earnings

This table compares Allogene Therapeutics and Immunovant's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	$-184,590,000.00	($1.83)	-17.73
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Allogene Therapeutics and Immunovant, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	0	3	13	0	2.81
Immunovant	0	1	14	0	2.93

Allogene Therapeutics currently has a consensus target price of $52.0833, indicating a potential upside of 60.55%. Immunovant has a consensus target price of $45.60, indicating a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Allogene Therapeutics.

Summary

Immunovant beats Allogene Therapeutics on 6 of the 10 factors compared between the two stocks.

Immunovant vs. Beam Therapeutics Stock

Beam Therapeutics (NASDAQ:BEAM) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Beam Therapeutics and Immunovant's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-529,075.00%	-103.41%	-48.05%
Immunovant	N/A	-34.80%	-32.38%

Valuation and Earnings

This table compares Beam Therapeutics and Immunovant's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$20,000.00	227,047.22	$-78,330,000.00	($14.05)	-5.17
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-10.01

Immunovant has lower revenue, but higher earnings than Beam Therapeutics. Immunovant is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 0.2% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Beam Therapeutics and Immunovant, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	0	3	3	0	2.50
Immunovant	0	1	14	0	2.93

Beam Therapeutics presently has a consensus target price of $96.00, suggesting a potential upside of 31.18%. Immunovant has a consensus target price of $45.60, suggesting a potential upside of 192.68%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Beam Therapeutics.

Summary

Immunovant beats Beam Therapeutics on 8 of the 12 factors compared between the two stocks.